Archimica

Archimica is a prominent contract development and manufacturing organization (CDMO) and active pharmaceutical ingredient (API) manufacturer headquartered in Lodi, Italy. With a heritage dating back to 1947, the company specializes in the development and large-scale commercial production of complex small molecule APIs and intermediates for both innovative and generic pharmaceutical markets. Archimica is recognized for its expertise in difficult-to-handle chemical technologies and maintains a robust portfolio of generic products, including Sucralfate and various oncology treatments. After several ownership transitions involving Clariant, Euticals, and AMRI, the company was acquired by PI Health Sciences in 2023 to serve as a strategic pillar for their global pharmaceutical expansion. The company continues to operate as a high-compliance manufacturing partner with a strong regulatory track record with the FDA and EMA.